Thursday 16 October, 2025
Introduction Long-acting injectable (LAI) products are formulations intended for prolonged drug release that offer several benefits including improved patient outcomes….
Read moreAbstracts
Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator
Thursday 16 October, 2025
Introduction: Glioblastoma (GBM) is an aggressive brain tumor for which there is no effective cure [1,2]. Therefore, there is an…
Read moreEnhancing statistical power in lipid-lowering therapy studies through optimization of the MACE endpoint composition: a model-based meta-analysis approach
Thursday 16 October, 2025
Introduction: Major adverse cardiac events (MACE) are used to assess the efficacy and safety of cholesterol-lowering compounds in late-stage clinical…
Read morePredicting Progression Free Survival from Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL)
Thursday 16 October, 2025
Introduction/Objectives: Measurable Residual Disease (MRD) is detectable and often quantifiable remnant cancer cells following treatment. The association between MRD and…
Read moreA case study of applying machine learning to improve non-invasive assessment of fibrosis stage in MASLD
Thursday 16 October, 2025
Introduction Metabolic dysfunction-associated steatohepatitis (MASH), the more severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), is a major cause…
Read moreTo quantify the association between tumor dynamics and overall survival across cancers: a Bayesian meta-analysis
Thursday 16 October, 2025
Context: In oncology clinical trials, the primary clinical endpoint is often overall survival (OS), which requires long study duration. Tumor size…
Read moreModel informed dose projection for SAB-176 using a joint time-to-event modeling approach in high-risk (HR) patients infected with Influenza
Thursday 16 October, 2025
Objectives: Influenza, a significant global health concern, can causes severe illness, hospitalizations, and death predominantly in high-risk (HR) groups, including…
Read moreFramework for Polyclonal Antibody Drug Development: Integrating Trial Data and Literature Models
Thursday 16 October, 2025
Objectives: In the pursuit of advancing immunotherapy for immune and autoimmune disorders, SAb has developed fully human, multi-targeted immunoglobulins (IgGs)…
Read moreCharacterization of the population dose-exposure-efficacy relationships of vamorolone, a synthetic corticosteroid drug in the treatment of Duchenne Muscular Dystrophy (DMD)
Thursday 16 October, 2025
Objectives: Vamorolone (Agamree) is a synthetic steroidal drug approved for the treatment of Duchenne Muscular Dystrophy (DMD), a life-threatening genetic…
Read morePopulation pharmacokinetic-pharmacodynamic modeling of the iclepertin drug effect on hemoglobin levels
Thursday 16 October, 2025
Introduction: Iclepertin (BI 425809) is a novel, potent and selective glycine transporter-1 (GlyT1) inhibitor currently in Phase III development to…
Read more